Clinical Trial Update: A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

A completed early-phase study evaluating the safety and efficacy of LentiGlobin BB305 in transfusion-dependent beta-thalassemia and sickle cell disease, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• LentiGlobin BB305 Drug Product (BB305)

Snippet

Sponsor: Genetix Biotherapeutics Inc. | Conditions: Beta-Thalassemia Major, Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-10